A CTL assay requiring only 150 μl of mouse blood

Journal of Immunological Methods

Volumn 233, Issue 1-2, 2000, Pages 1-11

  Swiniarski, Holly ^a   Sturmhoefel, Knut ^a   Lee, Kwang ^a   Wolf, Stanley F ^a   Dorner, Andrew J ^a   O'Toole, Margot ^a  

^a PFIZER INC   (United States)

Author keywords

CTL; Mouse; Peripheral blood

Indexed keywords

ANTIGEN; CYTOKINE;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; BLOOD; BLOOD CELL; CANCER GRAFT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNIZATION; INFLUENZA VIRUS; INTERMETHOD COMPARISON; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAMPLE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; MAST-CELL SARCOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED DBA; OLIGOPEPTIDES; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033972009     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00186-6     Document Type: Article

References (29)

1. Apostolopoulos V., Karanikas V., Haurum J.S., McKenzie I.F.C. Induction of HLA-A2-Restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159:1997;5211.
2. Berke, G., 1989. Functions and mechanisms of lysis induced by cytotoxic T lymphocytes and natural killer cells. Raven Press, New York.
3. Brandle D., Bilsborough J., Rulicke T., Uyttenhove C., Boon T., Van den Eynde B.J. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28:1998;4010.
4. 51Cr labeled allogenic target cells in vitro: inhibition by isoantibody and drugs Immunology. 14:1968;181.
5. Bucher D.J., Mikhail A., Popple S., Graves P., Meiklejohn G., Hodes D.S., Johansson K., Halonen P.E. Rapid detection of type A influenza viruses with monoclonal antibodies to the M protein (M1) by enzyme-linked immunosorbent assay and time-resolved fluoroimmunoassay. J. Clin. Microbiol. 29:1991;2484.
6. Ciernik I.F., Berzofsky J.A., Carbone D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156:1996;2369.
7. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P., Rosenberg S.A., Marincola F. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:1997;37.
8. Gajewski T.F. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:1996;465.
9. Gajewski T.F., Fallarino F., Uyttenhove C., Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 8:1996;2909.
10. Gordon B., Fong J., Papermaster B. Purification without loss of viability of neoplastic plasma-cells from the ascites passaged mouse myeloma, X5563. Blood. 29:1967;647.
11. k-restricted T-cell epitopes within the influenza A/PR/8/34 virus hemagglutinin. J. Virol. 65:1991;5401.
12. Harding F.A., Allison J.P. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1993;1791.
13. Jones B., Tite J.P., Janeway C.A. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones. J. Immunol. 136:1986;348.
14. Kim S.J., Sadelain M., Lee J.S., Seong R.H., Yun Y.S., Jang Y.J., Chung H.Y. Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line. Cancer Immunol. Immunother. 47:1999;257.
15. Lethe B., van den Eynde B., van Pel A., Corradin G., Boon T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:1992;2283.
16. Maeurer M.J., Storkus W.J., Kirkwood J.M., Lotze M.T. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 6:1996;11.
17. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T. Tumor regression responses in melanoma patients treated with a peptide encoded by gene mage-3. Int. J. Cancer. 80:1999;219.
18. Milan G., Zambon A., Cavinato M., Zanovello P., Rosato A., Collavo D. Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach. Virology. 73:1999;2280.
19. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Reinhad D., Burg G., Shadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine. 4:1998;328.
20. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine. 4:1998;321.
21. Siegmund, O.H., 1979. The Merck Veterinary Manual. In: O.H. Siegmund (Ed). Merck and Company, Rahway, NJ, p. 1472.
22. Taswell C., MacDonald H., Cerottini J. Clonal analysis of cytolytic T lymphocyte specificity: I. Phenotypically distinct sets of clones as the cellular basis of cross-reactivity to alloantigens. J. Exp. Med. 151:1980;1372.
23. Uyttenhove C., Maryanski J., Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1983;1040.
24. Van den Eynde B., Mazarguil H., Lethe B., Laval F., Gairin J.E. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur. J. Immunol. 24:1994;2740.
25. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643.
26. Van Pel A., De Plaen E., Boon T. Selection of highly transfectable variant from mouse mastocytoma P815. Somatic Cell Mol. Genet. 11(5):1985;467-475.
27. Wolfel T., Hauer M., Klehmann E., Brichard V., Ackermann B., Knuth A., Boon T., Meyer zum Buschenfelde K.-H. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int. J. Cancer. 55:1993;237.
28. Zeh H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. Immunology. 162:1999;989.
29. Zinkernagel R.M., Doherty P.C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness. Advances in Immunology. 27:1979;51.